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ABSTRACT
The study objective was to compare the efficacy of 
2 commercial dry cow mastitis formulations contain-
ing cloxacillin benzathine or ceftiofur hydrochloride. 
Quarter-level outcomes included prevalence of intra-
mammary infection (IMI) postcalving, risk for cure 
of preexisting infections, risk for acquiring a new IMI 
during the dry period, and risk for clinical mastitis 
between dry off and 100 d in milk (DIM). Cow-level 
outcomes included the risk for clinical mastitis and the 
risk for removal from the herd between dry off and 
100 DIM, as well as Dairy Herd Improvement Associa-
tion (DHIA) test-day milk component and production 
measures between calving and 100 DIM. A total of 799 
cows from 4 Wisconsin dairy herds were enrolled at dry 
off and randomized to 1 of the 2 commercial dry cow 
therapy (DCT) treatments: cloxacillin benzathine (DC; 
n = 401) or ceftiofur hydrochloride (SM; n = 398). 
Aseptic quarter milk samples were collected for routine 
bacteriological culture before DCT at dry off and again 
at 0 to 10 DIM. Data describing clinical mastitis cases 
and DHIA test-day results were retrieved from on-
farm electronic records. The overall crude quarter-level 
prevalence of IMI at dry off was 34.7% and was not 
different between treatment groups. Ninety-six percent 
of infections at dry off were of gram-positive organisms, 
with coagulase-negative Staphylococcus and Aerococcus 
spp. isolated most frequently. Mixed logistic regression 
analysis showed no difference between treatments as 
to the risk for presence of IMI at 0 to 10 DIM (DC = 
22.4%, SM = 19.9%) or on the risk for acquiring a new 
IMI between dry off and 0 to 10 DIM (DC = 16.6%, SM 
= 14.1%). Noninferiority analysis and mixed logistic 
regression analysis both showed no treatment difference 
in risk for a cure between dry off and 0 to 10 DIM 
(DC = 84.8%, SM = 85.7%). Cox proportional hazards 
regression showed no difference between treatments in 
quarter-level risk for clinical mastitis (DC = 1.99%, 
SM = 2.96%), cow-level risk for clinical mastitis (DC = 
17.0%, SM = 15.3%), or on risk for removal from the 
herd (DC = 10.7%, SM = 10.3%) between dry off and 
100 DIM. Finally, multivariable linear regression with 
repeated measures showed no overall no difference be-
tween treatments in DHIA test-day somatic cell count 
linear score (DC = 2.19, SM = 2.22), butterfat test (DC 
= 3.84%, SM = 3.86%), protein test (DC = 3.02%, SM 
= 3.02%), or 305-d mature-equivalent milk production 
(DC = 11,817 kg, SM = 11,932 kg) between calving 
and 100 DIM. In conclusion, DC was noninferior to 
SM in effecting a cure, and there was no difference in 
efficacy between these 2 DCT formulations as related 
to all other udder health or cow performance measures 
evaluated between dry off and 100 DIM.
Key words: dry cow mastitis, dry cow therapy, udder 
health, cure, intramammary infection
INTRODUCTION
Dry cow mastitis, which considers the persistence of 
preexisting IMI through the dry period as well as devel-
opment of new IMI (NIMI) during the dry period, is a 
critical determinant for subclinical and clinical mastitis 
in the next lactation (Smith et al., 1985; Erskine, 2001; 
Green et al., 2002). North American studies estimate 
that between 13 and 35% of quarters are infected sub-
clinically at dry off, and that between 8 and 25% of 
quarters develop a NIMI during the dry period (God-
den et al., 2003; Cook et al., 2005; Pantoja et al., 2009; 
Arruda et al., 2013a). Todhunter et al. (1995) estimated 
that 55% of environmental infections established early 
in the dry period persist into the next lactation and can 
possibly cause clinical mastitis flare ups. Bradley and 
Green (2000) reported that 52% of all clinical coliform 
mastitis cases occurring in the first 100 d of lactation 
may originate during the previous dry period.
Blanket dry cow therapy (DCT), or the practice of 
infusing all quarters with a long-acting antibiotic at 
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dry off, is a long-standing and widely adopted mastitis 
control strategy recommended by the National Mastitis 
Council (NMC). Blanket DCT works by curing exist-
ing subclinical infections caused by susceptible bacteria 
and by preventing NIMI that may be acquired during 
the early dry period. It is estimated that 72.3% of US 
dairy operations use blanket DCT, which corresponds 
to 81.7% of US dairy cows (USDA-NAHMS, 2008). 
Currently, 7 commercial DCT products have been ap-
proved by the Food and Drug Administration for use in 
US dairy herds (National Milk Producers Federation, 
2014). Milk and meat withholding period, minimum 
dry period length, claimed spectrum of action, and cost 
for these products vary considerably.
Whereas all DCT formulations available in the Unit-
ed States originally underwent testing to demonstrate 
efficacy against a negative control as a requirement for 
licensure by the Food and Drug Administration, rela-
tively few studies exist to compare efficacy among DCT 
products. One recent randomized clinical trial of 1,091 
cows from 6 commercial dairy herds in 4 states (CA, 
IA, MN, and WI) compared efficacy among 3 dry cow 
mastitis formulations: penicillin/dihydrostreptomycin, 
ceftiofur hydrochloride, and cephapirin benzathine 
(Arruda et al. 2013a,b). The results of that study indi-
cated no difference among the 3 DCT products studied 
regarding the prevalence of IMI postcalving, cure of 
preexisting IMI during the dry period, or development 
of new IMI during the dry period. Furthermore, that 
study reported no difference among the 3 treatments 
when considering quarter- and cow-level risk for a clini-
cal mastitis event before 100 DIM, removal from the 
herd before 100 DIM, and SCC linear score (LS) and 
milk production up to 100 DIM (Arruda et al., 2013a,b). 
In another study, Hallberg et al. (2006) evaluated the 
efficacy of different doses of ceftiofur hydrochloride for 
the treatment of existing IMI at dry off and prevention 
of NIMI during the dry period using a negative control 
and a positive control (cephapirin benzathine). How-
ever, that study was not designed to compare efficacy 
between the 2 different antimicrobial formulations used 
(ceftiofur hydrochloride vs. cephapirin benzathine). 
Furthermore, Hallberg et al. (2006) only enrolled cows 
with an elevated SCC (>400,000 cells/ mL) and results 
may not be generalizable to commercial dairy herds 
wherein blanket DCT is usually applied to all cows. A 
recent study conducted in Florida compared treatment 
with ceftiofur hydrochloride versus cephapirin benza-
thine at the cow level, but the authors did not report 
quarter-level outcomes such as risk for NIMI or risk for 
cure of preexisting IMI (Pinedo et al., 2012).
Although the aforementioned efficacy study conducted 
by Arruda et al. (2013a,b) provides producers with good 
information comparing the efficacy of the 3 available 
DCT formulations containing ceftiofur hydrochloride, 
cephapirin benzathine, and penicillin/dihydrostrep-
tomycin, additional comparative efficacy studies are 
needed to evaluate other DCT formulations available to 
North American dairy producers. One DCT formulation 
which is lacking comparative efficacy data is Dry-Clox 
(DC; Boehringer Ingelheim Vetmedica Inc., St Joseph, 
MO). Dry-Clox is composed of 500 mg of cloxacillin 
benzathine and is labeled for the treatment of mastitis 
during the dry period caused by Streptococcus agalactiae 
and Staphylococcus aureus, including penicillin-resistant 
strains. It has a 30-d meat withholding time postinfu-
sion and zero hour milk discard postcalving, following a 
minimum dry period length of 30 d. Another commonly 
used DCT formulation is Spectramast DC (SM; Zoetis, 
Florham Park, NJ), which is composed of 500 mg of 
ceftiofur hydrochloride and labeled for subclinical mas-
titis associated with Staphylococcus aureus, Streptococ-
cus dysgalactiae, and Streptococcus uberis. This product 
has a meat withdrawal period of 16 d postinfusion and, 
similar to DC, has a required dry period length of 30 d 
and no milk withholding time following calving. As both 
the DC and SM formulations are labeled against gram-
positive infections, have a 30-d required dry period, and 
have a zero hour milk discard following calving, it would 
be very useful for producers to know of any differences 
in efficacy when considering DCT products for use on 
their farm.
The current study objective was to compare the ef-
ficacy of DC (cloxacillin benzathine) versus SM (ceft-
iofur hydrochloride) as assessed by both quarter- and 
cow-level measures of udder health, as well as cow 
performance measures during the first 100 DIM. Our 
hypothesis was that quarters infused with DC at the 
time of dry off would have a noninferior proportion of 
quarters cured from preexisting IMI as compared with 
SM. Furthermore, we hypothesized no difference would 
be noted between DC and SM in terms of the quarter-
level risk for presence of IMI postcalving, the risk for 
acquiring NIMI during the dry period, and the risk for 
a clinical mastitis event between dry off and 100 DIM. 
At the cow-level we hypothesized no effect of treatment 
would be observed on risk for clinical mastitis or risk 
for removal from the herd (death or culling) between 
dry off and 100 DIM, and no difference in DHIA test-
day milk component and production measures during 
the first 100 DIM.
MATERIALS AND METHODS
Herd Selection
This randomized clinical trial was conducted in a 
convenience sample of 4 commercial Wisconsin Holstein 
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dairy farms between July 2014 and April 2015, under 
the University of Minnesota Institutional Animal Care 
and Use Committee. To be eligible to participate, herds 
needed to have a unique cow identification system (ear 
tag), be on a regular DHIA testing program (≥9 tests 
per year), and have a minimum 30-d target dry period 
length as required by the product label for the DC and 
SM products. Candidate herds were prescreened us-
ing bulk tank culture to ensure they were negative for 
Mycoplasma spp. Briefly, for each herd, bulk tank milk 
samples were collected on 5 consecutive days, frozen at 
−20°C, and then later thawed and commingled before 
culture for Mycoplasma spp. at the participating micro-
biology laboratory (Waupun Veterinary Service Milk 
Quality Laboratory, Waupun, WI). 
Cow Enrollment at Dry Off
All cow enrollment and sampling activities were 
completed by designated trained personnel within each 
herd, with training and supervision conducted by the 
principle investigator (A. P. Johnson). To be eligible for 
enrollment cows had to be in good general health, have 
4 functioning quarters, have not received parenteral or 
intramammary treatment with an antibacterial or anti-
inflammatory medication during a 30-d period imme-
diately before dry off, show no clinical signs of mastitis 
on the day of dry off, and have an expected dry period 
length greater than 30 d. Cows were dried off once per 
week in each herd. On dry off day, cows due to be dried 
off were brought into the parlor for their last milking 
and routine DCT. Animals were identified and visu-
ally inspected for clinical signs of illness, such as very 
low BCS (<2.0) or moderate-to-severe lameness, and 
the udder and milk were inspected for signs of clinical 
mastitis. Eligible cows were identified by application 
of a unique colored leg band attached to the rear leg 
and then randomly allocated to treat all 4 quarters 
with 1 of the 2 treatments (DC or SM) according to a 
previously prepared randomized spreadsheet created in 
Excel (Microsoft Corporation, Redmond, WA). Ran-
domization was blocked within farm for each day of 
enrollment (blocked every 6 cows).
Prior to sampling, routine udder preparation was 
performed by parlor staff. Whereas the type of predip 
used and sequence of predipping and forestripping was 
not identical among all herds, the general process in-
volved predipping, forestripping, redipping, leaving the 
dip on for at least 45 s of contact time, and then wiping 
teat barrel and teat end dry with a clean cloth towel. 
Following udder preparation, the designated sampling 
person disinfected the teat ends using gauze squares 
soaked in 70% isopropyl alcohol. Three strippings of 
fore milk were discarded and 10-mL duplicate quarter 
milk samples were aseptically collected into sterile vials 
identified with herd, cow number, quarter, and date. Af-
ter sample collection (S1 = sample 1), the final milking 
procedure took place and milk sample vials were placed 
into a chilled cooler on ice. Immediately following the 
final milking, all 4 teat ends were again scrubbed with 
alcohol-soaked gauze, the assigned treatment (DC or 
SM) was infused into each of the 4 quarters, and, fi-
nally, the internal teat sealant was infused into all quar-
ters of all cows (Orbeseal, Zoetis, New York, NY). All 
cows were postdipped with a disinfectant and moved to 
their respective dry cow facilities, where usual farm dry 
cow husbandry and management practices were under-
taken. Throughout the dry period, herd staff recorded 
any clinical mastitis events (cow identification, date, 
quarter) and other health events (e.g., abortion, death, 
culling). The S1 (enrollment) duplicate quarter milk 
samples were frozen at –20°C within 2 h of collection 
and shipped weekly to the microbiology laboratory for 
culture.
Postcalving Sampling and Follow-Up
Following calving, the designated personnel within 
each herd were to collect aseptic duplicate quarter 
milk samples (S2 = sample 2) once between 0 and 10 
DIM using the same sample collection procedure as 
was previously described for the S1 samples collected 
at dry off. All clinical mastitis events occurring in the 
first 100 DIM were recorded by farm staff using an on-
farm electronic record-keeping system (DairyComp305, 
Valley Agricultural Software, Tulare, CA), and farm 
personnel were asked to collect and freeze an aseptic 
milk sample from the affected quarter at time of detec-
tion of a clinical case. Clinical mastitis was defined as 
visibly abnormal milk accompanied or not by changes 
in the quarter. The S2 samples and clinical mastitis 
samples were frozen at −20°C on the farm and shipped 
weekly to the microbiology laboratory for culture. 
On-farm DairyComp305 software was used to capture 
health events (e.g., calving, death, culling, clinical mas-
titis) and DHIA test-day records [e.g., SCC LS, 305-d 
mature-equivalent milk yield (305ME; kg), butterfat 
percent, protein percent] for each test day for all study 
cows for the period between enrollment and 100 DIM.
Milk Culture Methods
All frozen S1, S2, and clinical mastitis samples from 
farms were placed on ice and transported to the local 
participating microbiology laboratory on a weekly basis 
(Waupun Veterinary Service Milk Quality Laboratory). 
Milk culture procedures followed published procedures 
recognized by the NMC for bovine mastitis (NMC, 
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1999). Only one of each pair of duplicate quarter sam-
ples collected at dry off (S1) and calving (S2) was rou-
tinely selected for microbial culture. The second paired 
sample was kept frozen in reserve and only cultured in 
cases where the first sample was contaminated. Samples 
to be cultured were thawed to room temperature and 
0.01 mL of milk was plated onto blood and MacConkey 
agar (BD, Franklin Lakes, NJ) using calibrated loops. 
Inoculated plates were incubated at 37°C for 48 h and 
then observed for bacterial growth. For plates with 
bacterial growth, the number of colonies was recorded 
for each species isolated and colonies were reisolated on 
blood agar for further characterization. Colony mor-
phology, hemolysis pattern, and Gram staining results 
were described.
Further characterization of gram-positive organ-
isms involved the catalase test reaction to differentiate 
Staphylococcus and Streptococcus species and then co-
agulase testing. Organisms that were catalase positive 
and coagulase negative were reported as CNS, whereas 
catalase- and coagulase-positive organisms were re-
ported as Staphylococcus aureus. Catalase-negative 
organisms had their identity confirmed by the API 
Streptococcus identification system (bioMerieux-Vitek 
Inc., Hazelwood, MO). Pathogens reported as other 
Streptococcus spp. corresponded to subspecies of Strep-
tococcus that are less commonly reported in literature 
or to pathogens that could not be identified by the API 
Streptococcus system. Gram-positive organisms that 
were in very low prevalence and could not be identi-
fied with biochemical tests were reported as other gram 
positive. Further characterization of gram-negative 
organisms involved testing with the API20E system 
(bioMerieux-Vitek Inc.). Organisms that could not be 
identified by the API system were reported as other 
gram negative. Finally, nonbacterial pathogens such as 
yeast were reported as other. If 3 or more pathogens 
were present in a single sample, it was considered con-
tamination and the duplicate sample was cultured. If 
the duplicate sample was also contaminated then the 
quarter sample was reported as contaminated. Blinding 
of the sample collectors or producer on farm at the 
time of enrollment was not possible; however, labora-
tory personnel were blinded to treatment.
Definitions
Presence of IMI. An IMI was defined as one or 
more colonies isolated from a 0.01-mL milk sample for 
all pathogens except for CNS and Bacillus spp. For 
CNS, 2 or more colonies isolated from a 0.01-mL milk 
sample were needed to establish presence of an IMI 
(Dohoo et al., 2011a). For Bacillus spp, an IMI was de-
fined as 5 or more colonies isolated from a 0.01-mL milk 
sample. As no peer-reviewed studies exist determining 
a cut-off point for the latter organism, the definition for 
IMI for Bacillus spp. was established during an infor-
mal discussion among mastitis experts conducted dur-
ing the Mastitis Research Workers’ Conference (Nov 
1, 2011, Chicago, IL). A single IMI was defined as the 
presence of only one type of pathogen in the sample, 
whereas mixed infections corresponded to the presence 
of 2 different bacterial species.
Bacteriological Cure. A cure was defined as the 
failure to culture 1 or 2 of the pathogens originally 
present at the dry off sample in the postcalving sample 
(S2). For a mixed infection present at S1, both organ-
isms had to be absent in the S2 sample to classify the 
quarter as cured. Quarters that had contaminated or 
missing samples were excluded from this analysis.
NIMI. A NIMI was defined as quarters from which 
no pathogens were recovered at dry off (S1) but growth 
was later detected in the postcalving sample (S2) or 
a different (new) pathogen was recovered at S2 as 
compared with S1. Quarters that had contaminated or 
missing samples were excluded from this analysis. It 
was possible for the same quarter to experience both a 
cure and a NIMI.
Data Analysis
Sample Size Calculations. For the a priori sample 
size calculation for the noninferiority portion of our 
study, the primary outcome considered was risk for a 
cure between dry off and 0 to 10 DIM. The minimum 
difference in cure rate to declare noninferiority of 
DC, as compared with SM, was prestated at 10%. To 
demonstrate noninferiority, a total of 339 cows (1356 
quarters) per group were estimated to be required as-
suming α = 0.025 and β = 0.2, with 10% inflation to 
adjust for within-herd clustering of cows, and assuming 
that 30% of the quarters would be infected at dry off 
and therefore at risk for a cure (non-inferiority tests for 
two proportions, PASS 2008; NCSS, Kaysville, UT). 
However, this number was inflated to 390 cows (1,560 
quarters) per group to account for an anticipated 15% 
loss to follow-up due to culling, missing samples, or 
contaminated samples.
Description of Cow and Quarter Character-
istics at Enrollment. All statistical analyses were 
conducted using SAS version 9.3 (SAS Institute Inc., 
Cary, NC). Descriptive statistics were generated for ex-
ploratory data analysis and basic diagnostic techniques 
were used to evaluate normality and presence of outli-
ers. Characteristics of cows and quarters assigned to 
the 2 treatment groups, including previous lactation 
length (days), parity, dry period length (days), previous 
lactation LS at last DHIA test before dry off (DryLS), 
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and previous lactation total milk, fat, and protein pro-
duction (kg) were compared at baseline (dry off) using 
ANOVA.
Effect of Treatment on Quarter-Level Mea-
sures of Udder Health. Univariable logistic regression 
(GLIMMIX procedure) was first used to investigate the 
relationship between treatment (DC or SM) and each 
of the following quarter-level binary outcomes: (1) risk 
for presence of IMI at S1, (2) risk for presence of IMI 
at S2, (3) risk for cure between dry off and 0 to 10 
DIM, and (4) risk for NIMI between dry off and 0 to 10 
DIM. Herd was forced into all models as a fixed effect 
to account for the clustering of cows within herd. A 
term describing quarter within cow was included in all 
quarter-level models as a random statement to adjust 
for the clustering of quarters within cow. Univariable 
logistic regression was also used to investigate if other 
cow characteristics were associated with each of the 
aforementioned 4 outcome variables, including parity, 
DryLS, previous lactation total milk, fat or protein pro-
duction (kg), previous lactation length (days), and dry 
period length (days), all offered as continuous variables.
Main effects significant at P < 0.20 in the previously 
described univariable models were carried forward to 
offer to a multivariable model investigating the effect 
of treatment (DC vs. SM; forced) on the 4 outcome 
variables of interest. A backward stepwise approach 
was then used to remove nonsignificant variables one 
at a time, starting with the least significant variable 
first (largest P-value), until only significant variables 
remained (P < 0.05). Potential confounders were inves-
tigated; to be a potential confounder, a variable had to 
be significantly associated with both the explanatory 
variable (treatment group) and the outcome variable of 
interest for a given model. A variable was identified as 
a confounder and retained in the model if its exclusion 
from the model resulted in >15% change in the esti-
mate of the effect of treatment on the outcome variable 
of interest. All models were investigated for the pres-
ence of an interaction between treatment and all other 
significant variables, but no interactions were found to 
exist. Models were compared during the model building 
process using the −2 log-likelihood statistic and model 
fit was evaluated by use of the Hosmer and Lemeshow 
goodness-of-fit test. Noninferiority analysis of the effect 
of treatment with DC on risk for a bacteriological cure 
was completed by calculating the cure rate difference 
(95% CI) for DC as compared with SM, and then com-
paring the lower bound of the CI for the rate difference 
for DC against the critical value, Δ (0.10; Piaggio et 
al., 2006).
Effect of Treatment on Risk for Clinical Mas-
titis and Risk for Removal from the Herd by 100 
DIM. All quarters and cows enrolled were considered at 
risk for a clinical mastitis event and for removal from the 
herd between dry off and 100 DIM. After describing the 
crude proportions affected, Cox proportional hazards 
regression (PHREG procedure) was used to describe 
the effect of treatment on risk for each of the following 
time-to-event outcomes occurring between enrollment 
and 100 DIM: (1) quarter-level risk for a clinical masti-
tis event, (2) cow-level risk for a clinical mastitis event, 
and (3) cow-level risk for removal from the herd (death 
or culling). For each of these 3 models, the failure date 
was defined as the date when the event of interest (i.e., 
clinical mastitis or removal) was first reported between 
enrollment and 100 DIM. For the clinical mastitis 
time-to-event models, quarters or cows not reported to 
experience clinical mastitis by 100 DIM were classified 
as right censored at the cow’s culling or death date (if 
removed before 100 DIM) or were right-censored at 100 
DIM. For the herd removal time-to-event model, cows 
not reported to experience a removal event by 100 DIM 
were right-censored at 100 DIM. Apart from the terms 
describing treatment and herd, which were both forced, 
other explanatory variables investigated for inclusion 
in these models using a backward elimination process 
(as previously described) included parity, DryLS, previ-
ous lactation total milk, fat or protein production (kg), 
previous lactation length (days), and dry period length 
(days). An interaction effect between treatment and all 
other significant covariates was investigated but was 
found not to be present. Because the Cox model as-
sumes a proportional hazard constant over time, this 
assumption was tested by creating a time dependent 
variable [treatment × log(time)] inside the PHREG 
procedure and testing this term for proportionality 
using the proportionality_test statement. The results 
of the proportionality test were not significant for the 
3 time-to-event models, indicating the models did not 
violate the assumption that proportional hazards were 
constant over time.
Effect of Treatment on DHIA Test-Day Mea-
sures of LS, Components, and Milk Production 
in Early Lactation. Mixed linear regression (MIXED 
procedure) was used to investigate the effect of treat-
ment on each of the following 4 DHIA test-day outcome 
measures for all DHIA test days occurring between 
calving and 100 DIM: (1) SCC LS, (2) butterfat test 
(%), (3) protein test (%), and (4) 305ME milk yield 
(kg). For all 4 models, treatment and herd were forced 
as a fixed effect, with repeated measures on each DHIA 
test number (1, 2, or 3). Other explanatory variables 
investigated for inclusion in these models included DIM 
on test day, parity, previous lactation dryLS, previous 
lactation total milk, fat and protein production (kg), 
and dry period length (days). Univariate analysis was 
initially conducted to evaluate the relationship between 
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each of the aforementioned explanatory variables and 
the dependent variable of interest. Variables signifi-
cant at P < 0.2 in the univariate analysis were carried 
forward to offer into the full model. Nonsignificant 
variables were then removed from the model using a 
backward stepwise approach with final significance 
declared at P < 0.05. A variable was considered a con-
founder and retained in the final model if its inclusion 
in the model changed the estimate of the effect of the 
DCT treatment group on the dependent variable by 
15% or greater. First-order interactions between treat-
ment group and all other significant main effects terms 
were tested. Models were compared during the model 
building process using the −2 Log-likelihood statistic, 
and model fit was evaluated by plotting marginal and 
conditional residuals.
RESULTS
Herd Characteristics
This convenience sample of 4 Holstein herds averaged 
1,663 lactating cows, with an average bulk tank SCC of 
172,500 cells/mL and tank average milk production of 
40.3 kg/cow per day. Other herd production informa-
tion, bedding, and housing characteristics are described 
in Table 1. All herds routinely used blanket dry cow 
therapy and an internal teat sealant at dry off (Or-
beseal, Zoetis), as well as a coliform mastitis vaccine 
program (Enviracor J-5, Zoetis; 4 shots, delivered at 
dry off, 3–4 wk precalving, 21 d postcalving, and 90 d 
postcalving).
Cow Characteristics at Enrollment
A total of 799 cows (3,196 quarters) were enrolled 
between June 5 and October 6, 2014, with 401 cows 
(1,604 quarters) and 398 cows (1,592 quarters) enrolled 
into the DC and SM groups, respectively. Cow numbers 
were relatively equally distributed among the 4 partici-
pating herds, with 177, 207, 202, and 213 cows enrolled 
from herds 1, 2, 3, and 4, respectively. A similar balance 
of cows were assigned to the DC and SM treatment 
groups within each herd: herd 1: DC = 87, SM = 90; 
herd 2: DC = 108, SM = 99; herd 3: DC = 100, SM = 
102; and herd 4: DC = 106, SM = 107. Analysis of vari-
ance showed that enrollment characteristics, including 
parity, Dry LS, and previous lactation total milk, fat, 
and protein yield, were not different for cows between 
the 2 treatment groups. Also dry period length was not 
different between groups (P > 0.10 for all comparisons; 
Table 2). Overall, the mean (±SD) parity, DryLS, and 
previous lactation total milk, fat, and protein yield for 
all cows was 2.7 ± 1.0, 3.1 ± 1.9, 13,432 kg ± 3,763, 
490 ± 109 kg, and 409 ± 109 kg, respectively. The 
mean dry period length for all cows was 58.0 ± 10.8 d.
IMI Status at Dry Off
Of the 3,196 quarters originally enrolled, 208 quarters 
(6.5%) were omitted due to contamination of the S1 
sample collected at dry off, leaving 2,988 quarters for 
analysis of infection status at dry off. The rate of con-
taminated samples at dry off was not different between 
treatment groups (DC = 6.6%, or 106 of 1,608; SM 
= 6.4%, or 102 of 1,588). When examining the crude 
prevalence of IMI at dry off, the overall prevalence of 
IMI (all quarters) and the prevalence of IMI by herd 
was 34.7% (overall) and 41.3, 19.9, 51.4, and 30.5% 
for herds 1, 2, 3, and 4, respectively (Table 3). The 
overall proportion of infections caused by gram-positive 
organisms was 95.7%, but ranged between 89.1 (herd 
1) and 99.6% (herd 4). Conversely, the overall propor-
tion of infections at dry off caused by gram-negative 
organisms was 4.3%, ranging between 0.4 (herd 4) and 
10.9% (herd 1; Table 3). Whereas CNS was the pre-
dominant organism recovered for all herds, the relative 
frequency of this and other types of gram-positive and 
gram-negative infections varied by herd (Table 3).
The crude proportion of quarters with IMI present 
at dry off was similar between the DC group (35.4%, 
Table 1. Herd characteristics
Item Herd 1 Herd 2 Herd 3 Herd 4 Average
Size (no. of lactating cows) 1,550 1,500 1,100 2,500 1,663
Milk production (kg/cow per day) 32.7 44.5 40.9 43.2 40.3
Bulk tank SCC1 (cells/mL) 164,000 122,000 194,000 210,000 172,500
Bulk tank protein (%) 3.39 3.13 2.97 3.19 3.17
Bulk tank fat (%) 4.0 3.56 3.65 3.96 3.79
Housing during far-off dry period2 Freestalls Freestalls Freestalls Freestalls —
Bedding during far-off dry period2 Biosolids Recycled sand New sand Recycled sand —
Housing during close-up dry period3 Bedded pack Freestalls Freestalls Freestalls —
Bedding during close-up dry period3 Straw Recycled sand Biosolids Recycled sand —
1Bulk tank milk SCC average.
2Far-off dry period is from dry off to approximately 30 d precalving.
3Close-up dry period is approximately 30 d precalving to calving.
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or 532 of 1,502) and the SM group (34.1%, or 506 of 
1,486). The final mixed logistic model showed no as-
sociation between treatment and the risk for presence 
of IMI at dry off [DC = 35.2%; SM = 33.8%; odds 
ratioDC = 1.06 (0.91, 1.25), P = 0.45; Table 4]. A posi-
tive association was observed between DryLS and risk 
for IMI at dry off. A negative association was noted 
between parity and risk for IMI at dry off. There were 
significant differences among the 4 herds in risk for 
presence of IMI at dry off (Table 4). Gram-positive 
and -negative species represented 95.7 and 4.3% of all 
isolates present at dry off, respectively (Table 5). The 
most frequent gram-positive isolates were CNS (69.5%), 
Aerococcus spp. (9.4%), and Bacillus spp. (7.0%); the 
most frequent gram-negative isolate was Escherichia 
coli (1.4%).
Effect of Treatment on Risk for Presence of Infection 
Between 0 and 10 DIM
A total of 2,551 quarters were used for evaluation 
of the risk for presence of IMI after calving (0 to 10 
DIM). From the 3,196 quarters originally enrolled (DC 
= 1,608; SM = 1,588) a total of 645 quarters (20.2%) 
Table 2. Enrollment characteristics of cows infused with Dry-Clox1 or Spectramast DC2 at dry off3
Parameter
Treatment group
Dry-Clox Spectramast DC
Number of cows 401 398
Parity 2.65 ± 0.95 2.75 ± 0.97
Previous lactation length (d) 340 ± 63.8 344 ± 64.4
SCC linear score at dry off 3.07 ± 1.89 3.21 ± 1.96
Previous lactation fat yield (kg) 484 ± 131 493 ± 144
Previous lactation protein yield (kg) 405 ± 105 410 ± 113
Previous lactation milk yield (kg) 13,406 ± 3,716 13,403 ± 3,798
Dry period length (d) 58.4 ± 9.8 57.6 ± 11.7
1Dry-Clox (500 mg cloxacillin benzathine; Boehringer Ingelheim Vetmedica, Inc., St Joseph, MO).
2Spectramast DC (500 mg ceftiofur hydrochloride; Zoetis, Florham Park, NJ). 
3Table reports mean ± SD; ANOVA showed no treatment group difference for any parameter (P > 0.10 for 
all comparisons).
Table 3. Crude prevalence and frequency of bacterial species for quarters with infection present at dry off, by herd
Item
IMI present at dry off, no. (%)
Herd 1 Herd 2 Herd 3 Herd 4 Total
Total number of quarters sampled1 676 821 677 814 2,988
Quarters with bacterial growth 279 (41.3) 163 (19.9) 348 (51.4) 248 (30.5) 1,038 (34.7)
Quarters with no bacterial growth 397 (58.7) 658 (80.1) 329 (48.6) 566 (69.5) 1,950 (65.3)
Gram positive
 Aerococcus spp. 34 (11.2) 51 (30.0) 5 (1.3) 15 (5.7) 105 (9.4)
 Bacillus spp. 12 (3.9) 2 (1.2) 62 (16.4) 2 (0.8) 78 (7.0)
 CNS 214 (70.4) 64 (37.6) 286 (75.7) 211 (80.2) 775 (69.5)
 Corynebacterium spp. 1 (0.3) 0 (0) 0 (0) 0 (0) 1 (0.1)
 Enterococcus spp. 2 (0.7) 26 (15.3) 6 (1.6) 20 (7.6) 54 (4.8)
 Streptococcus dysgalactiae 0 (0) 0 (0) 1 (0.3) 1 (0.4) 2 (0.2)
 Streptococcus uberis 0 (0) 0 (0) 5 (1.3) 0 (0) 5 (0.5)
 Streptococcus agalactiae 1 (0.3) 0 (0) 0 (0) 0 (0) 1 (0.1)
 Staphylococcus aureus 0 (0) 0 (0) 3 (0.8) 1 (0.4) 4 (0.4)
 Other gram positive 7 (2.3) 21 (12.4) 2 (0.5) 12 (4.6) 42 (3.8)
 Total gram positive 271 (89.1) 164 (96.5) 370 (97.9) 262 (99.6) 1,067 (95.7)
Gram negative
 Escherichia coli 14 (4.6) 0 (0) 1 (0.3) 0 (0) 15 (1.4)
 Enterobacter spp. 7 (2.3) 0 (0) 0 (0) 0 (0) 7 (0.6)
 Klebsiella spp. 1 (0.3) 4 (2.3) 3 (0.8) 0 (0) 8 (0.7)
 Proteus spp. 1 (0.3) 0 (0) 0 (0) 0 (0) 1 (0.1)
 Pseudomonas spp. 1 (0.3) 0 (0) 0 (0) 0 (0) 1 (0.1)
 Serratia spp. 3 (1.0) 0 (0) 1 (0.3) 1 (0.4) 5 (0.5)
 Other gram negative 6 (2.0) 2 (1.2) 3 (0.8) 0 (0) 11 (1.0)
 Total gram negative 33 (10.9) 6 (3.5) 8 (2.1) 1 (0.4) 48 (4.3)
Total isolates 304 (100) 170 (100) 378 (100) 263 (100) 1,115 (100)
1Excludes contaminated samples.
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Table 4. Final mixed models describing factors associated with risk for IMI at dry off and after calving, for cows infused with Dry-Clox1 or 
Spectramast DC2 at dry off3
Parameter (level)
Adjusted proportion  
(95% CI)
b coefficient  
(SE)
Odds ratio  
(95% CI)
Type III  
P-value
Model: Risk for IMI present at dry off    
 Intercept  NR4 −0.40 (0.16) NR 0.011
 Dry cow treatment 0.45
  Dry-Clox 35.2% (32.7, 37.8) 0.061 (0.081) 1.06 (0.91, 1.25)
  Spectramast DC 33.8% (31.4, 36.4) Referent 1.0
 Dry LS5 NR 0.098 (0.022) NR <0.0001
 Parity NR −0.28 (0.047) NR <0.0001
 Herd <0.0001
  Herd 1 41.4% (37.6, 45.3) 0.48 (0.11) 1.62 (1.30, 2.01)
  Herd 2 21.3% (18.5, 24.5) −0.47 (0.12) 0.62 (0.49, 0.78)
  Herd 3 48.1% (44.2, 52.1) 0.7 (0.11) 2.13 (1.71, 2.65)
  Herd 4 30.4% (27.2, 33.7) Referent 1.0
Model: Risk for IMI present at 0 to 10 DIM    
 Intercept NR −2.85 (0.16) NR <0.0001
 Dry cow treatment 0.16
  Dry-Clox 22.4% (20.0, 25.0) 0.15 (0.10) 1.16 (0.95, 1.41)
  Spectramast DC 19.9% (17.6, 22.6) Referent 1.0
 Herd <0.0001
  Herd 1 40.6% (33.5, 45.9) 2.40 (0.19) 11.02 (7.66, 15.85)
  Herd 2 37.2% (33.8, 40.7) 2.26 (0.17) 9.56 (6.88, 13.29)
  Herd 3 17.0% (14.2, 20.3) 1.20 (0.18) 3.32 (2.31, 4.77)
  Herd 4 5.8% (4.4, 7.7) Referent 1.0  
1Dry-Clox (500 mg cloxacillin benzathine; Boehringer Ingelheim Vetmedica Inc., St Joseph, MO).
2Spectramast DC (500 mg ceftiofur hydrochloride; Zoetis, Florham Park, NJ). 
3Models adjusted for clustering of quarter-within-cow as a random effect.
4NR = not reported. 
5Somatic cell count linear score at last DHIA test before dry off.
Table 5. Crude prevalence and frequency of bacterial species for quarters with infection present at dry off or at 0–10 DIM
Item
IMI present at dry off, no. (%)
 
IMI present at 0–10 DIM, no. (%)
DC1 SM2 Total DC1 SM2 Total
Total number of quarters 1,502 1,486 2,988  1,307 1,244 2,551
Quarters with growth 532 (35.4) 506 (34.0) 1,038 (34.7)  319 (24.4) 268 (21.5) 587 (23.0)
Quarters with no growth 970 (64.6) 980 (66.0) 1,950 (65.3)  988 (75.6) 976 (78.5) 1,964 (77.0)
Gram positive
 Aerococcus spp. 50 (8.7) 55 (10.2) 105 (9.4)  120 (35.2) 96 (33.0) 216 (34.2)
 Bacillus spp. 43 (7.4) 35 (6.5) 78 (7.0)  12 (3.5) 12 (4.1) 24 (3.8)
 CNS 396 (68.5) 379 (70.6) 775 (69.5)  134 (39.3) 130 (44.7) 264 (41.8)
 Corynebacterium spp. 1 (0.2) 0 (0) 1 (0.1)  0 (0) 0 (0) 0 (0)
 Enterococcus spp. 38 (6.6) 16 (3.0) 54 (4.8)  33 (9.7) 23 (7.9) 56 (8.9)
 Streptococcus dysgalactiae 2 (0.4) 0 (0) 2 (0.2)  0 (0) 0 (0) 0 (0)
 Streptococcus uberis 1 (0.2) 4 (0.7) 5 (0.5)  0 (0) 0 (0) 0 (0)
 Streptococcus agalactiae 1 (0.2) 0 (0) 1 (0.1)  0 (0) 0 (0) 0 (0)
 Staphylococcus aureus 3 (0.5) 1 (0.2) 4 (0.4)  3 (0.9) 0 (0) 3 (0.5)
 Other gram positive 25 (4.3) 17 (3.2) 42 (3.8)  8 (2.4) 6 (2.1) 14 (2.2)
 Total gram positive 560 (96.9) 507 (94.4) 1,067 (95.7)  310 (90.9) 267 (91.8) 577 (91.3)
Gram negative
 Escherichia coli 6 (1.0) 9 (1.7) 15 (1.4)  17 (5.0) 5 (1.7) 22 (3.5)
 Enterobacter spp. 2 (0.4) 5 (0.9) 7 (0.6)  0 (0) 0 (0) 0 (0)
 Klebsiella spp. 3 (0.5) 5 (0.9) 8 (0.7)  4 (1.2) 9 (3.1) 13 (2.1)
 Proteus spp. 0 (0) 1 (0.2) 1 (0.1)  0 (0) 0 (0) 0 (0)
 Pseudomonas spp. 0 (0) 1 (0.2) 1 (0.1)  0 (0) 0 (0) 0 (0)
 Serratia spp. 3 (0.5) 2 (0.4) 5 (0.5)  1 (0.30 3 (1.0) 4 (0.6)
 Other gram negative 4 (0.7) 7 (1.3) 11 (1.0)  9 (2.6) 7 (2.4) 16 (2.5)
 Total gram negative 18 (3.1) 30 (5.6) 48 (4.3)  31 (9.1) 24 (8.2) 55 (8.7)
Total isolates 578 (100) 537 (100) 1,115 (100)  341 (100) 291 (100) 632 (100)
1Dry-Clox (500 mg cloxacillin benzathine; Boehringer Ingelheim Vetmedica Inc., St Joseph, MO).
2Spectramast DC (500 mg ceftiofur hydrochloride; Zoetis, Florham Park, NJ).
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were omitted for the following reasons: 28 quarters were 
for cows that either died or were culled during the dry 
period (DC = 20, SM = 8), 28 quarters were from cows 
that calved prematurely before meeting the 30-d dry 
period required to be on label for the 2 treatment prod-
ucts (DC = 8, SM = 20), 205 quarters were omitted 
because a postcalving sample was not collected by herd 
staff (DC = 77, SM = 128), 288 quarters were omitted 
because a postcalving milk sample was collected later 
than 10 DIM (DC = 136, SM = 152), and 96 quarters 
were omitted because the postcalving sample was con-
taminated (DC = 60, SM = 36). Of all 645 quarters 
omitted from this analysis, the proportion omitted was 
similar between the DC group (18.7%, or 301 of 1,608) 
and the SM group (21.7%, or 344 of 1,588).
The crude proportion of quarters with IMI present 
at 0 to 10 DIM was similar between the DC group 
(24.3%, or 318 of 1,307) and the SM group (21.5%, or 
268 of 1,244). The final mixed logistic model showed no 
effect of treatment on the risk for presence of IMI at 
0 to 10 DIM in the DC group (22.4%) versus the SM 
group [19.9%; odds ratioDC = 1.16 (0.95, 1.41), P = 
0.16; Table 4]. Significant differences were noted among 
the 4 herds in risk for presence of IMI at 0 to 10 DIM 
(Table 4). Gram-positive and -negative species repre-
sented 91.3 and 8.7%, of all isolates in recovered from 
S2 samples, respectively (Table 5). The most frequent 
gram-positive isolates were CNS (41.8%), Aerococcus 
spp. (34.2%), and Enterococcus spp. (8.9%); the most 
frequent gram-negative isolates were Escherichia coli 
(3.5%) and Klebsiella spp. (2.1%; Table 5).
Effect of Treatment on Risk for Developing a New 
Infection Between Dry Off and 0 to 10 DIM
From the 2,988 quarters with uncontaminated S1 
samples at enrollment (DC = 1,502; SM = 1,486) 605 
quarters (20.2%) were omitted from final analysis of 
risk for new IMI for the following reasons: 23 quarters 
were from cows that either died or were culled during 
the dry period (DC = 15, SM = 8), 20 quarters were 
from cows that calved prematurely before meeting the 
30-d dry period required on label for the 2 treatment 
products (DC = 4, SM = 16), 193 quarters were omit-
ted because a postcalving (S2) sample was not collected 
by herd staff (DC = 75, SM = 118), 280 quarters were 
omitted because the S2 milk sample was collected later 
than 10 DIM (DC = 131, SM = 149), and 89 quarters 
were omitted because the S2 sample was contaminated 
(DC = 53, SM = 36). Of all 605 quarters omitted 
from this analysis, the proportion omitted was similar 
between the DC group (18.5%, or 278 of 1,502) and 
the SM group (22.0%, or 327 of 1,486). In the end, 
2,383 quarters (DC = 1,224, SM = 1,159) were used for 
evaluation of effect of treatment on the risk for develop-
ing a new IMI between dry off and 0 to 10 DIM.
The crude proportion of quarters with a new IMI 
acquired between dry off and 0 to 10 DIM was similar 
between the DC group (19.9%, or 244 of 1,224) and the 
SM group (17.1%, or 198 of 1,159). The final mixed 
logistic regression model showed no difference between 
treatments in risk for acquiring a new IMI in the DC 
group (16.6%) versus the SM group [14.1%; odds ra-
tioDC = 1.21 (0.96, 1.51), P = 0.10; Table 6]. Significant 
differences were observed among the 4 herds in risk for 
acquiring a new IMI between dry off and 0 to 10 DIM. 
A total of 89.3 and 10.7% of all new IMI were caused 
by gram-positive and -negative organisms, respectively. 
The most frequent gram-positive isolates causing NIMI 
were Aerococcus spp. (40.6%), CNS (32.1%), and En-
terococcus spp. (9.9%); the most frequent gram-negative 
isolates causing NIMI were Escherichia coli (4.2%) and 
Klebsiella spp. (2.7%; Table 7).
Effect of Treatment on Risk for a Cure Between  
Dry Off and 0 to 10 DIM
This analysis began by considering the 2,383 quarters 
(DC = 1,224, SM = 1,159) that were used in the previ-
ously described analysis of risk for a new IMI. However, 
the quarter also had to have IMI present at dry off, 
therefore putting it at risk for a cure. After exclud-
ing 1,609 noninfected quarters at dry off (DC = 819, 
SM = 790), 774 quarters (DC = 405, SM = 369) were 
included in the final analysis of effect treatment on risk 
for cure. The crude proportion of quarters experiencing 
a cure between dry off and 0 to 10 DIM was similar be-
tween the DC group (84.9%, or 344 of 405) and the SM 
group (85.4%, or 315 of 369). The final mixed logistic 
regression model showed no difference in the risk for 
experiencing a cure in the DC group (84.8%) versus the 
SM group [85.7%; odds ratioDC = 0.93 (0.58, 1.51), P = 
0.75: Table 6]. Significant differences were noted among 
the 4 herds in risk for experiencing a cure between dry 
off and 0 to 10 DIM (Table 5). A total of 95.3 and 4.7% 
of all cures were of prior gram-positive and -negative 
infections, respectively (Table 7).
As the trial did not show a significant difference 
between DC and SM, the goal was then to identify 
whether the conclusion of no difference may result 
in a noninferiority claim. The claim of noninferiority 
was based on the left-hand side of the 95% confidence 
interval of the rate difference being smaller than the 
predefined noninferiority limit of Δ, defined a priori 
as 10% (or 0.10). The cure rate estimates (95% CI) for 
DC [0.8480 (0.7995, 0.8865)] and SM [0.8567 (0.8069, 
0.8954) groups were used to calculate the cure rate dif-
ference (95% CI) for DC as being −0.0087 (−0.0708, 
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Table 6. Final mixed models describing effect of treatment on risk for acquiring a new infection and risk for experiencing a cure between dry 
off and 0 to 10 DIM, for cows infused with Dry-Clox1 or Spectramast-DC2 at dry off3
Parameter (level)
Adjusted proportion, %  
(95% CI)
b coefficient  
(SE)
Odds ratio  
(95% CI)
Type III  
P-value
Model: Risk for acquiring a new IMI between dry off and 0 
to 10 DIM
 
 Intercept NR4 −3.24 (0.19) NR <0.0001
 Dry Cow Treatment 0.102
  Dry-Clox 16.6 (14.3, 19.1) 0.19 (0.11) 1.21 (0.96, 1.51)
  Spectramast DC 14.1 (12.0, 16.5) Referent 1.0
 Herd <0.0001
  Herd 1 31.7 (26.8, 37.0) 2.37 (0.22) 10.74 (6.97, 16.57)
  Herd 2 32.6 (29.3, 36.1) 2.42 (0.20) 11.23 (7.56, 16.66)
  Herd 3 9.9 (7.5, 12.9) 0.93 (0.23) 2.54 (1.59, 4.07) 
  Herd 4 4.1 (2.9, 5.8) Referent 1.0
Model: Risk for experiencing a cure between dry off and 0 to 
10 DIM
 
 Intercept NR 2.79 (0.30) NR <0.0001
 Dry Cow Treatment 0.75
  Dry-Clox 84.8 (80.0, 88.7) −0.069 (0.21) 0.93 (0.58, 1.51)
  Spectramast DC 85.7 (80.7, 89.5) Referent 1.0
 Herd 0.0073
  Herd 1 75.0 (65.3, 82.7) −1.66 (0.34) 0.19 (0.086, 0.42)
  Herd 2 80.2 (71.7, 86.6) −1.36 (0.34) 0.26 (0.12, 0.56)
  Herd 3 85.3 (79.4, 89.8) −1.0 (0.33) 0.37 (0.17, 0.79)
  Herd 4 94.0 (89.3, 96.7) Referent 1.0  
1Dry-Clox (500 mg cloxacillin benzathine; Boehringer Ingelheim Vetmedica Inc., St Joseph, MO).
2Spectramast DC (500 mg ceftiofur hydrochloride; Zoetis, Florham Park, NJ). 
3Models adjusted for clustering of quarter-within-cow as a random effect.
4NR = not reported.
Table 7. Crude proportion and frequency of bacterial species for new infections and cures between dry off and at 0–10 DIM
Item
New IMI
 
Cures
DC1 SM2 Total DC1 SM2 Total
Total number of quarters at risk for the event 1,244 1,159 2,383  405 369 774
Quarters experiencing the event [no. (%)]3 244 (19.9) 198 (17.1) 442 (18.6)  344 (84.9) 315 (85.4) 659 (85.1)
Gram positive [no. (%)]3
 Aerococcus spp. 108 (41.7) 85 (39.2) 193 (40.6)  29 (7.8) 35 (10.5) 64 (9.0)
 Bacillus spp. 11 (4.3) 6 (2.8) 17 (3.6)  30 (8.0) 23 (6.9) 53 (7.5)
 CNS 78 (30.1) 75 (34.6) 153 (32.1)  249 (66.6) 219 (65.6) 468 (66.1)
 Corynebacterium spp. 0 (0) 0 (0) 0 (0)  1 (0.3) 0 (0) 1 (0.1)
 Enterococcus spp. 26 (10.0) 21 (9.7) 47 (9.9)  30 (8.0) 13 (3.9) 43 (6.1)
 Streptococcus dysgalactiae 0 (0) 0 (0) 0 (0)  1 (0.3) 0 (0) 1 (0.1)
 Streptococcus uberis 0 (0) 0 (0) 0 (0)  0 (0) 3 (0.9) 3 (0.4)
 Streptococcus agalactiae 0 (0) 0 (0) 0 (0)  1 (0.3) 0 (0) 1 (0.1)
 Staphylococcus aureus 1 (0.4) 0 (0) 1 (0.2)  2 (0.5) 1 (0.3) 3 (0.4)
 Other gram positive 8 (3.1) 6 (2.8) 14 (2.9)  22 (5.9) 16 (4.8) 38 (5.4)
 Total gram positive 232 (89.6) 193 (88.9) 425 (89.3)  365 (97.6) 310 (92.8) 675 (95.3)
Gram negative [no. (%)]3
 Escherichia coli 15 (5.8) 5 (2.3) 20 (4.2)  2 (0.5) 6 (1.8) 8 (1.1)
 Enterobacter spp. 0 (0) 0 (0) 0 (0)  0 (0) 1 (0.3) 1 (0.1)
 Klebsiella spp. 4 (1.5) 9 (4.2) 13 (2.7)  3 (0.8) 5 (1.5) 8 (1.1)
 Proteus spp. 0 (0) 0 (0) 4 (0.8)  0 (0) 0 (0) 0 (0)
 Pseudomonas spp. 0 (0) 0 (0) 0 (0)  0 (0) 0 (0) 0 (0)
 Serratia spp. 1 (0.4) 3 (1.4) 4 (0.8)  2 (0.5) 1 (0.3) 3 (0.4)
 Other gram negative 7 (2.7) 7 (3.2) 14 (2.9)  2 (0.5) 11 (3.3) 13 (1.8)
 Total gram negative 27 (10.4) 24 (11.1) 51 (10.7)  9 (2.4) 24 (7.2) 33 (4.7)
Total isolates [no. (%)]3 259 (100) 217 (100) 476 (100)  374 (100) 334 (100) 708 (100)
1Dry-Clox (500 mg cloxacillin benzathine; Boehringer Ingelheim Vetmedica Inc., St Joseph, MO).
2Spectramast DC (500 mg ceftiofur hydrochloride; Zoetis, Florham Park, NJ). 
3[n (%)]: n refers to number of events and the fraction (%) refers to the proportion of all events.
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0.0534). Because the lower bound of the CI for the rate 
difference (0.0708) was to the right of the critical value, 
Δ (0.10), it can be concluded that DC was noninferior 
relative to SM to effect a bacteriological cure during 
the dry period (Figure 1).
Effect of Treatment on Risk for a Clinical Mastitis 
Event and on Risk for Removal from the Herd 
Between Dry Off and 100 DIM
For quarter-level mastitis, the crude proportion of 
quarters experiencing a clinical mastitis event between 
dry off and 100 DIM was similar between the DC group 
(2.99%, 48 of 1,608) and the SM group (2.96%, 47 
of 1,588). The final Cox proportional hazards regres-
sion model found no difference between treatments as 
to the risk for a quarter-level clinical mastitis event 
between dry off and 100 DIM [hazard ratioSM = 0.95 
(0.64, 1.43), P = 0.82; Table 8]. A significant effect 
of herd and a positive association between parity and 
quarter-level clinical mastitis risk were noted (Table 
8). Although quarter samples were not made available 
for culture from all clinical mastitis events reported by 
farm staff (3/95 or 3.2% missing), culture results from 
those samples submitted show 53.3% with no bacterial 
growth, 33.7% with gram-positive growth, 12.0% with 
gram-negative growth, and 1.1% with other (yeast; 
Table 9).
For cow-level mastitis, the crude proportion of cows 
experiencing a clinical mastitis event between dry 
off and 100 DIM was similar between the DC group 
(16.96%, 68 of 401) as compared with the SM group 
(15.33%, 61 of 398). The final Cox proportional haz-
ards regression model also found no difference between 
treatments in risk for a cow-level clinical mastitis event 
between dry off and 100 DIM [hazard ratioSM = 0.89 
(0.63, 1.25), P = 0.50; Table 8]. A positive associa-
tion between parity and cow-level clinical mastitis risk 
was observed. Whereas herd was not significant, it was 
forced into the model to control for clustering of cows 
within herd (Table 8).
The crude proportion of cows removed from the herd 
between dry off and 100 DIM was similar between the 
DC group (10.7%, 43 of 401) as compared with the 
SM group (10.3%, 41 of 398). The final Cox propor-
tional hazard regression model also found no difference 
between treatments in risk for removal from the herd 
during this period [hazard ratioSM = 0.97 (0.63, 1.50), 
P = 0.91; Table 8]. A positive association between par-
ity and removal risk was seen. Although herd was not 
significant, it was forced into the model to control for 
clustering of cows within herd (Table 8).
Effect of Treatment on DHIA Test-Day Measures  
of LS, Components, and Milk Production  
in Early Lactation 
A total of 2,226 DHIA test-day records were recorded 
between calving and 100 DIM, including 757 first test-
day events (DC = 377, SM = 380), 745 second test-day 
events (DC = 372, SM = 373), and 724 third test day 
events (DC = 364, SM = 360). The mean (±SD) DIM 
at first, second, and third DHIA test events was 14.9 
(±8.6), 42.8 (±10.1), and 71.1 (±13.4), respectively. 
Figure 1. Difference in cure rate [−0.0087 (−0.0708, 0.0534)] between Dry-Clox (DC; 84.8% cured) and Spectramast DC (SM; 85.7% cured) 
in the noninferiority trial, where the critical difference (Δ) is shown relative to the observed difference and associated 95% CI. The shaded area 
indicates zone of noninferiority.
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After controlling for parity, DIM on test day, and herd 
as fixed effects, the final repeated measures linear 
regression models showed no difference between treat-
ments as to the test-day LS (DC = 2.19, SM = 2.22, P 
= 0.68), butterfat test (DC = 3.84%, SM = 3.86%, P 
= 0.48), protein test (DC = 3.02%, SM = 3.02%, P = 
0.83), and 305ME (DC = 11,817 kg, SM = 11,932 kg, 
P = 0.11; Table 10). However, because the latter model 
estimating the effect of treatment on 305ME (kg) found 
a significant treatment by herd interaction, the data 
Table 8. Results of Cox proportional hazards regression estimating the effect of treatment on quarter- and cow-level clinical mastitis risk, and 
on risk for removal from the herd between dry off and 100 DIM, for cows infused with Dry-Clox1 or Spectramast DC2 at dry off
Parameter (Level)
Crude proportion 
affected, %  
(n of N)
b coefficient  
(SE)
Hazard ratio  
(95% CI)
Type III  
P-value
Model: Risk for quarter-level clinical mastitis event   
 Dry Cow Treatment 0.82
  Spectramast DC 2.96 (47 of 1,588) −0.048 (0.21) 0.95 (0.64, 1.43)
  Dry-Clox 2.99 (48 of 1,608) Referent
 Parity  NR3 0.21 (0.093) 1.23 (1.03, 1.48) 0.024
 Herd NR 9.15 × 10−6 (1.29 × 10−6) NR <0.0001
Model: Risk for cow-level clinical mastitis event   
 Dry Cow Treatment 0.50
  Spectramast DC 15.3 (61 of 398) −0.12 (0.18) 0.89 (0.63, 1.25)
  Dry-Clox 17.0 (68 of 401) Referent
 Parity NR 0.21 (0.083) 1.23 (1.05, 1.45) 0.012
 Herd NR 1.22 × 10−6 (8.02 × 10−6) NR 0.13
Model: Risk for removal from the herd   
 Dry Cow Treatment 0.91
  Spectramast DC 10.3 (41 of 398) −0.026 (0.22) 0.97 (0.63, 1.50)
  Dry-Clox 10.7 (43 of 401) Referent
 Parity NR 0.46 (0.09) 1.59 (1.33, 1.89) <0.0001
 Herd NR 4.42 × 10−7 (9.88 × 10−7) NR 0.65
1Dry-Clox (500 mg cloxacillin benzathine; Boehringer Ingelheim Vetmedica, Inc., St Joseph, MO).
2Spectramast DC (500 mg ceftiofur hydrochloride; Zoetis, Florham Park, NJ). 
3NR = not reported.
Table 9. Crude proportion and frequency of bacterial species from clinical mastitis events occurring between 
dry off and 100 DIM, for quarters infused with Dry-Clox1 or Spectramast DC2 at dry off
Item
Clinical mastitis cases
DC1 SM2 Total
Total number of quarters at risk for clinical mastitis 1,608 1,588 3,196
Quarters experiencing clinical mastitis [no. (%)]3 48 (2.99) 47 (2.96) 95 (2.97)
No culture result (sample not submitted) 1 2 3
Known culture result (samples submitted for culture) 47 45 92
No bacterial growth4 23 (48.9) 26 (57.8) 49 (53.3)
Gram positive [no. (%)]4
 Aerococcus spp. 0 (0) 4 (8.9) 4 (4.3)
 Bacillus spp. 2 (4.3) 1 (2.2) 3 (3.3)
 CNS 6 (12.8) 5 (11.1) 11 (12.0)
 Corynebacterium spp. 1 (2.1) 0 (0) 1 (1.1)
 Enterococcus spp. 2 (4.3) 3 (6.7) 5 (5.4)
 Other gram positive 3 (6.4) 4 (8.9) 7 (7.6)
 Total gram positive 14 (29.9) 17 (37.8) 31 (33.7)
Gram negative [no. (%)]4
 Escherichia coli 7 (14.9) 1 (2.2) 8 (8.7)
 Klebsiella spp. 1 (2.1) 0 (0) 1 (1.1)
 Other gram negative 1 (2.1) 1 (2.2) 2 (2.2)
 Total gram negative 9 (19.1) 2 (4.4) 11 (12.0)
Other,4 yeast 1 (2.1) 0 (0) 1 (1.1)
1Dry-Clox (500 mg cloxacillin benzathine; Boehringer Ingelheim Vetmedica, Inc., St Joseph, MO).
2Spectramast DC (500 mg ceftiofur hydrochloride; Zoetis, Florham Park, NJ). 
3[n (%)]: n refers to number of events and the fraction (%) refers to the proportion of all events.
4[n (%)]: refers to the number of events and the fraction (%) refers to the proportion of only those clinical 
mastitis events with a known culture result.
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was stratified by herd and reanalyzed. Stratified analy-
sis showed a positive effect of treatment with DC in 
herd 4 (DC = 12,729 kg, SM = 12,383 kg, P = 0.014), 
a negative effect of treatment with DC in herd 3 (DC = 
11,843 kg, SM = 12,520 kg, P < 0.0001), and no effect 
of treatment with DC in herd 1 (DC = 9,952 kg. SM = 
10,091 kg, P = 0.21) and herd 2 (DC = 12,707 kg, SM 
= 12,763 kg, P = 0.69; models not shown).
DISCUSSION
Ours is the first multiherd randomized clinical trial 
conducted in North American dairy herds designed 
specifically to compare efficacy between DC (cloxacillin 
benzathine) and SM (ceftiofur hydrochloride) in terms 
of udder health and cow performance during the first 
100 d of lactation. Strengths of the current study in-
clude a large sample size (adequate power), successful 
randomization of cows to treatment (i.e., similar base-
line characteristics), and the fact that it was conducted 
in multiple commercial herds using different housing 
systems (freestall, bedded pack) and different bedding 
materials (recycled sand, biosolids, straw) during the 
dry period. An additional strength is the longer-term 
follow-up of cows and quarters beyond the immediate 
postpartum period. When conducting treatment effi-
cacy studies such as this one, it is important not only 
describe the effect of treatment on bacteriological find-
ings in the immediate postpartum period, but also on 
other longer-term and more clinically and economically 
relevant outcomes such as SCC, milk production, clini-
cal mastitis risk, and culling risk.
One possible limitation that could affect generaliz-
ability of results is that, whereas study herds had 
similar average milk production (40.3 kg/cow per day) 
and SCC (172,500 cells/mL) as compared with other 
Midwest herds with more than 1,000 cows (40.5 kg/
cow per day, 179,000 cells/mL), study herds were larger 
(1,663 lactating cows), produced more milk, and had 
lower average SCC as compared with Midwest Hol-
stein herds of all sizes (185 lactating cows, 33.2 kg/
cow per day, 213,000 cells/mL; AgSource Cooperative 
Services, Vernon, WI). Study herds were also larger 
than average for all US dairy herds (167 lactating cows; 
USDA-NAHMS, 2010). Finally, all study herds used 
an internal teat sealant at dry off (Orbeseal, Zoetis) 
and a coliform mastitis vaccine (Enviracor J-5, Zoetis). 
The 2007 NAHMS study reported that approximately 
30% of all operations, and approximately 49% of larger 
operations with ≥500 cows, routinely use an internal 
teat sealant (USDA-NAHMS, 2008). Similarly, approxi-
mately 38% of all operations reported vaccinating for 
coliform mastitis (USDA-NAHMS, 2010). As such, al-
though results of that study are generalizable to herds 
similar to those used in the current study, future studies 
could investigate if findings are similar in smaller herds 
or herds not routinely using internal teat sealants at 
dry off.
Another point for discussion is whether or not it 
was a limitation in the study design that IMI status 
after calving was assessed using only a single sample 
collected between 0 to 10 DIM. The decision to use 
a single sample was based upon our belief that col-
lecting a single sample would not negatively affect the 
validity of study findings. A previous study evaluating 
the relative sensitivity and specificity of diagnosing IMI 
using a single sample (vs. multiple samples), reported 
that triplicate samples collected over consecutive days 
provided only a modest gain in specificity and little or 
no gain in sensitivity as compared with a single sample 
(Dohoo et al., 2011b). As such, we do not consider the 
use of a single sample for diagnosing IMI after calv-
Table 10. Results of final main effects linear regression models describing the effect of treatment on DHIA 
test day linear score, milk components, and milk yield between calving and 100 DIM, for cows infused with 
Dry-Clox1 or Spectramast DC2 at dry off3
Outcome variable  Treatment group
Adjusted mean  
(SE)
b coefficient  
(SE)
Type III  
P-value
SCC linear score Dry-Clox 2.19 (0.06) −0.03 (0.08) 0.68
Spectramast DC 2.22 (0.06) Referent
Butter fat (%) Dry-Clox 3.84 (0.02) −0.02 (0.03) 0.48
Spectramast DC 3.86 (0.02) Referent
Protein (%) Dry-Clox 3.02 (0.01) −0.003 (0.014) 0.83
Spectramast DC 3.02 (0.01) Referent
305ME4 (kg) Dry-Clox 11,817 (50.8) −115.5 (71.8) 0.11
Spectramast DC 11,932 (50.8) Referent  
1Dry-Clox (500 mg cloxacillin benzathine; Boehringer Ingelheim Vetmedica, Inc., St Joseph, MO).
2Spectramast DC (500 mg ceftiofur hydrochloride; Zoetis, Florham Park, NJ). 
3All models adjusted for DIM on test day, parity, and herd as fixed effects, plus repeated measures by test day 
number (1, 2, 3).
4305ME = 305-d mature-equivalent milk yield.
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ing to be a limitation. Furthermore, our finding of no 
difference in IMI rate at calving is supported by the 
longer-term observations associated with udder health 
in that no effect of treatment on clinical mastitis risk or 
on SCC LS measures were observed over all DHIA tests 
occurring between 0 and 100 DIM. It makes biologi-
cal sense that if IMI rates at calving did not differ by 
treatment group, then clinical mastitis risk and early 
lactation SCC LS measures should also not differ by 
treatment group, as it is well understood that SCC is 
elevated as an inflammatory response to infection, and 
that quarters infected at calving will have increased 
risk for clinical mastitis and increased SCC measures 
in early lactation (Barkema et al., 1999; Schukken et 
al., 2003).
When considering the short-term quarter-level 
outcomes, no difference between groups was noted in 
prevalence of IMI at dry off, and no difference was 
noted in efficacy as measured by cure risk or risk for 
new IMI between dry off and 0 to 10 DIM. As such, 
it was not surprising that no treatment difference was 
observed in the risk for presence of IMI at 0 to 10 DIM. 
Overall, the crude prevalence of IMI at dry off (34.7%) 
and calving (23.0%), the incidence of cure (85.1%), and 
the incidence of NIMI (18.5%) for the current study 
were similar with results of other North American dry 
cow mastitis studies. Previous studies have reported 
the prevalence of IMI to range between 12.8 and 32% at 
dry off and between 6.9 and 22.8% postcalving, respec-
tively (Godden et al., 2003; Pantoja et al., 2009; Ar-
ruda et al., 2013a). Also, previous studies have reported 
NIMI incidence and cure rates during the dry period 
to vary between 6 and 36% (NIMI) and between 61.8 
and 88.9% (cures), respectively (Godden et al., 2003; 
Cook et al., 2005; Hallberg et al., 2006; Pantoja et al., 
2009; Gundelach et al., 2011; Arruda et al., 2013a). 
Regarding the relatively low cure rates for ceftiofur hy-
drochloride (61.8%) reported by Hallberg et al., (2006), 
it should be noted that their study only enrolled cows 
with a high SCC, which may have represented more 
chronic infections that were less likely to cure.
That the current study found no difference in effi-
cacy between DC and SM is consistent with the fact 
that both DCT products are labeled to be effective 
against one or more gram-positive organisms, and that 
the majority of IMI detected in the current study were 
caused by gram-positive organisms. Neither of the 2 
products evaluated are labeled against gram-negative 
organisms, even though it is recognized that they will 
have different degrees of gram-negative activity in in 
vitro tests, with SM expected to have more activity 
against gram-negative organisms than DC (Salmon et 
al., 1996; Oliver and Murinda, 2012). These findings 
are in agreement with previous dry cow studies that 
report varying but relatively low proportions of IMI 
caused by gram-negative pathogens at dry off, with es-
timates ranging between 0.25 and 22% (Godden et al., 
2003; Hallberg et al., 2006; Pantoja et al., 2009; Arruda 
et al., 2013a). In the current study, only 4.3% of all 
subclinical IMI present at dry off (and therefore at risk 
for a cure) were caused by a gram-negative organism. 
Similarly, only 10.7% of NIMI acquired during the dry 
period were caused by a gram-negative organism. It is 
possible that SM might prove to be more efficacious 
than DC in herds with a greater proportion of dry cow 
mastitis infections caused by gram-negative organisms. 
However, this hypothesis requires testing in a different 
set of herds with a greater proportion of infections pres-
ent at dry off or a greater proportion of NIMI acquired 
during the dry period caused by gram-negative organ-
isms.
The current study reported very few infections at dry 
off caused by the contagious pathogens, Staph. aureus 
(0.4% of IMI) and Strep. agalactiae (0.1% of IMI). The 
low number of Staph. aureus and Strep. agalactiae com-
mon to all study herds is consistent with other dry cow 
studies in the United States (Arruda et al., 2013a) and 
very likely reflects good overall mastitis control pro-
grams. This includes the implementation of the Five-
Point Program, a program developed at the National 
Institute for Research in Dairying in England that was 
adopted by progressive herds to control and prevent 
IMI caused by contagious pathogens. 
Given that no difference was seen between treatments 
as to the prevalence of IMI at 0 to 10 DIM, it was not 
surprising that we also found no difference between 
treatments in the early lactation measures of udder 
health and cow performance, including quarter- and 
cow-level risk for a clinical mastitis event between dry 
off and 100 DIM, cow-level risk for removal from the 
herd between dry off and culling, and DHIA test-day 
results between calving and 100 DIM, including LS, 
butterfat test, protein test, and 305ME milk produc-
tion. The overall crude incidence of clinical mastitis 
occurring between dry off and 100 DIM at the quar-
ter- (3.0%) and cow-level (16.1%) was very similar to 
previous dry cow mastitis studies which have reported 
early lactation clinical mastitis incidence rates ranging 
between 3 and 6% (quarter-level) or between 10.1 and 
14.2% (cow-level; Godden et al., 2003; Gundelach et al., 
2011; Pinedo et al., 2012; Arruda et al., 2013a). The 
overall crude removal rate between enrollment and 100 
DIM for the current study (10.5%) was consistent with 
Arruda et al. (2013b), which reported a 9% removal rate 
from calving to 100 DIM. In the current study, most of 
these events occurred after calving; very few quarter-
level clinical mastitis cases (5.3% or 5 of 95 quarters 
affected), cow-level clinical mastitis cases (2.3%, or 3 of 
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129 cows affected), and cow removal events (8.3%, or 7 
of 84 cows removed) occurred in the period between dry 
off and calving. Although no treatment difference was 
observed in DHIA test d 305ME milk yield, we cannot 
explain why we found a treatment by herd interaction, 
nor specifically why a positive effect of treatment was 
seen with DC in herd 4, a negative effect in herd 3, and 
no effect in herds 1 and 2.
CONCLUSIONS
Results from this randomized clinical trial demon-
strate that, in herds using blanket Orbeseal infusion 
at dry off and a coliform mastitis vaccination program, 
and where gram-positive infections represented >90% 
of subclinical IMI present at dry-off and after calving, 
there was no difference in efficacy between DC and SM 
regarding risk for presence of IMI at 0 to 10 DIM, risk 
for experiencing a cure during the dry period, risk for 
developing a NIMI between dry off and 0 to 10 DIM, 
and risk for experiencing a clinical mastitis event at 
either the quarter- or cow-level between dry off and 
100 DIM. Similarly, no difference was noted between 
treatments for risk of removal from the herd between 
dry off and 100 DIM, or for DHIA test-day measures 
during the first 100 DIM including LS, milk butterfat 
and protein percentage, and 305ME milk production.
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